These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2895352)

  • 1. Follow-up of neuropathy from 2',3'-dideoxycytidine.
    Dubinsky RM; Dalakas M; Yarchoan R; Broder S
    Lancet; 1988 Apr; 1(8589):832. PubMed ID: 2895352
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of capecitabine in cancer: management of the hand foot syndrome.
    Sudoyo AW
    Acta Med Indones; 2005; 37(3):174-6. PubMed ID: 16110178
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC).
    Dubinsky RM; Yarchoan R; Dalakas M; Broder S
    Muscle Nerve; 1989 Oct; 12(10):856-60. PubMed ID: 2558314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral neuropathy induced by 2',3'-dideoxycytidine. A rabbit model of 2',3'-dideoxycytidine neurotoxicity.
    Anderson TD; Davidovich A; Arceo R; Brosnan C; Arezzo J; Schaumburg H
    Lab Invest; 1992 Jan; 66(1):63-74. PubMed ID: 1309930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral neuropathy: zalcitabine reassessed.
    Carey P
    Int J STD AIDS; 2000 Jul; 11(7):417-23. PubMed ID: 10919481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients.
    Berger AR; Arezzo JC; Schaumburg HH; Skowron G; Merigan T; Bozzette S; Richman D; Soo W
    Neurology; 1993 Feb; 43(2):358-62. PubMed ID: 8382349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).
    Yarchoan R; Perno CF; Thomas RV; Klecker RW; Allain JP; Wills RJ; McAtee N; Fischl MA; Dubinsky R; McNeely MC
    Lancet; 1988 Jan; 1(8577):76-81. PubMed ID: 2891981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy.
    Martinez OP; French MA
    AIDS; 1993 Jun; 7(6):901-2. PubMed ID: 8395858
    [No Abstract]   [Full Text] [Related]  

  • 9. The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys.
    Kelley JA; Litterst CL; Roth JS; Vistica DT; Poplack DG; Cooney DA; Nadkarni M; Balis FM; Broder S; Johns DG
    Drug Metab Dispos; 1987; 15(5):595-601. PubMed ID: 2891473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
    Schønnemann KR; Yilmaz M; Andersen M; Pfeiffer P
    Acta Oncol; 2011 Jan; 50(1):151-2. PubMed ID: 20843172
    [No Abstract]   [Full Text] [Related]  

  • 11. Ultrastructure of peripheral neuropathy induced in rabbits by 2',3'-dideoxycytidine.
    Feldman D; Brosnan C; Anderson TD
    Lab Invest; 1992 Jan; 66(1):75-85. PubMed ID: 1309931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exacerbation of peripheral neuropathy by lamivudine.
    Cupler EJ; Dalakas MC
    Lancet; 1995 Feb; 345(8947):460-1. PubMed ID: 7853984
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanically-evoked C-fiber activity in painful alcohol and AIDS therapy neuropathy in the rat.
    Chen X; Levine JD
    Mol Pain; 2007 Feb; 3():5. PubMed ID: 17319957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.
    Cooney DA; Dalal M; Mitsuya H; McMahon JB; Nadkarni M; Balzarini J; Broder S; Johns DG
    Biochem Pharmacol; 1986 Jul; 35(13):2065-8. PubMed ID: 3015143
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2',3'-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate.
    Keilbaugh SA; Hobbs GA; Simpson MV
    Mol Pharmacol; 1993 Oct; 44(4):702-6. PubMed ID: 8232219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
    Briani C; Argyriou AA; Izquierdo C; Velasco R; Campagnolo M; Alberti P; Frigeni B; Cacciavillani M; Bergamo F; Cortinovis D; Cazzaniga M; Bruna J; Cavaletti G; Kalofonos HP
    J Peripher Nerv Syst; 2014 Dec; 19(4):299-306. PubMed ID: 25582667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PKC-mediated HuD-GAP43 pathway activation in a mouse model of antiretroviral painful neuropathy.
    Sanna MD; Quattrone A; Ghelardini C; Galeotti N
    Pharmacol Res; 2014 Mar; 81():44-53. PubMed ID: 24565699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
    Michalaki V; Gennatas S; Gennatas K
    Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The RNA-binding protein HuD promotes spinal GAP43 overexpression in antiretroviral-induced neuropathy.
    Sanna MD; Quattrone A; Mello T; Ghelardini C; Galeotti N
    Exp Neurol; 2014 Nov; 261():343-53. PubMed ID: 24861443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spinal RyR2 pathway regulated by the RNA-binding protein HuD induces pain hypersensitivity in antiretroviral neuropathy.
    Sanna MD; Peroni D; Quattrone A; Ghelardini C; Galeotti N
    Exp Neurol; 2015 May; 267():53-63. PubMed ID: 25765490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.